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Abstract
The cannabinoid type-2 G protein-coupled (CB2) receptor is an emerging therapeutic target for pain management
and immune system modulation. In a mouse model of Alzheimer’s disease (AD) the orally administered natural
product 4′-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by
inhibiting neuroinflammation. In this commentary we discuss an intriguing link between the recently found CB2
receptor-mediated molecular mechanisms of MH and its anti-inflammatory and protective effects in AD animal
models. We argue that the novel cannabimimetic MH may exert its beneficial effects via modulation of CB2
receptors expressed in microglial cells and astrocytes. The recent findings provide further evidence for a potential
role of CB2 receptors in the pathophysiology of AD, spurring target validation and drug discovery.
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Background
In a recent study published in Journal of Neuroinflam-
mation Lee and colleagues report that the natural product
4′-O-methylhonokiol (MH) from Magnolia grandiflora
L. potently inhibits lipopolysaccharide (LPS)-induced
amyloidogenesis via anti-inflammatory mechanisms [1].
They have shown that chronic oral administration of 1
mg/kg of MH in mice strongly ameliorates LPS-induced
memory impairment via inhibition of nuclear factor
kappa B (NF-κB) and the gene expression of inducible
nitric oxide synthase and cyclooxygenase-2. MH also
inhibited the activation of astrocytes in the brain. The
same group recently reported that MH attenuates the
development of Alzheimer’s disease (AD) in Tg2576 mice
[2], and inhibits different signaling cascades related to
oxidative stress and mitogen-activated protein (MAP)
kinases [3-5]. In the European patent application
EP2327402A2 by Bioland Ltd. the authors report the
invention of a method for treating or preventing amyloid-
related diseases comprising administering a pharma-
ceutically effective dosage of MH or pharmaceutically
acceptable salt thereof [6]. In this patent it is mentioned
that MH inhibits acetylcholinesterase (AChE) and in a
subsequent study it was shown that MH inhibits AChE
activity at nM concentrations in vitro [7]. In yet another
study by the same group, MH was shown to inhibit
hydrogen peroxide and Aβ(1-42)-induced neurotoxicity
in cultured neurons, as well as PC12 cells, by prevention
of the reactive oxygen species generation and directly
inhibited β-secretase activity and Aβ fibrilization in vitro
[8]. Thus, MH could be a useful agent to prevent the
neuroinflammation-associated pathogenesis or the pro-
gression of AD. However, beyond the AChE inhibition,
none of the studies describe any molecular interaction of
MH and its anti-inflammatory mechanism of action
therefore remains elusive. In their article, Lee et al. sug-
gested that inhibition of NF-κB and MAP kinases or the
general antioxidative properties of MH are potential
mechanisms by which this biphenyl natural product
inhibits inflammation and amyloidogenesis [1]. However,
from the data presented it is not clear whether the inhib-
ition of signaling is a primary or secondary event, for ex-
ample to receptor modulation. Moreover, some signaling
effects were only observed at high nM or even μM con-
centrations in vitro which do not necessarily reflect the
physiological concentrations in the brain. We therefore
comment on a recently discovered molecular mechanism
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of action of MH that could well explain some of the
anti-inflammatory effects observed.
MH is a novel modulator of CB2 receptors
and inflammation
In a previous study we have shown that MH is a potent
and selective cannabinoid type-2 G protein-coupled
(CB2) receptor ligand (hCB2 Ki = 44 nM), triggering a
novel type of heteroactive signaling (EC50 ~ 10 nM) [9].
In an in vitro profiling comprising more than 40 recep-
tors MH was highly specific towards cannabinoid CB2
receptors at nM concentrations. Furthermore, MH did
not interact with cannabinoid type-1 (CB1) receptors,
which in the brain are predominantly expressed in neu-
rons, and found in presynaptic sites of GABAergic and
glutamatergic synapses where they in a retrograde man-
ner inhibit the release of these neurotransmitters [10-
12]. Whereas CB1 receptors mainly mediate the central
side effects of cannabinoids, CB2 receptors are primarily
associated with a broad range of inflammatory processes
[13-16]. CB2 receptors are largely absent in the central
nervous system (CNS) under normal conditions, but are
upregulated in microglial cells and astrocytes under neu-
roinflammatory stimulation as it occurs in AD [17,18].
Indeed, CB2 receptors appear to mediate many of the
anti-inflammatory actions of endocannabinoids, the ara-
chidonic acid-derived lipids which non-specifically target
cannabinoid receptors [19,20]. There is an overall agree-
ment that endocannabinoids are released during oxida-
tive and inflammatory stress and counterbalance
inflammation by inducing a TH1-TH2 cytokine shift, al-
though the exact mechanisms are not understood
[14,21,22]. In our study we have shown that MH po-
tently inhibits LPS-stimulated TNF-α expression and
chemotaxis in macrophages in an apparently CB2
receptor-dependent manner, exerting anti-inflammatory
and anti-osteoclastogenic effects [9].
A role for CB2 receptors in the pathophysiology of AD
The report by Lee et al. [1] is interesting because it links
MH with the already established anti-inflammatory
effects mediated via CB2 receptors in the brain. Since
MH can act as both inverse agonist and agonist, depend-
ing on the specific signal pathway [9], it will be interest-
ing to study the potentially positive and negative roles of
CB2 receptor signal transduction in models of AD. A
prominent effect of MH is the inhibition of macrophage
migration induced by the endocannabinoid 2-
arachidonoyl glycerol (2-AG), even though MH shows
anti-inflammatory properties similar to 2-AG and other
endocannabinoids [9]. Interestingly, the CB2 receptor
mediates myeloid progenitor cell trafficking in the CNS,
thus controlling inflammation in the brain [23]. The
novel functionally heteroactive (dualistic) CB2 receptor
ligand MH thus both inhibits and mimics the action of
2-AG via different pathways. Of note, 2-AG is the major
arachidonic acid metabolite in the brain and a key lipid
of the leukotriene network in the CNS [24]. It decreases
brain edema, inflammation and infarct volume and
improves clinical recovery via cannabinoid receptors
[25,26]. Like 2-AG, MH can trigger calcium signaling in
myeloid cells in a CB2 receptor-dependent manner [9].
Intriguingly, in this context, CB2 receptors have been
directly associated with AD. It was shown that the acti-
vation of CB2 receptors stimulates in situ and in vitro
β-amyloid removal by human macrophages [27]. Canna-
binoids acting at CB2 receptors block β-amyloid-induced
activation of cultured microglial cells and abrogate
microglia-mediated neurotoxicity after β-amyloid addi-
tion to rat cortical co-cultures [28]. Furthermore, in-
creased CB2 receptor expression was also found in
neuritic plaque-associated astrocytes and microglia in
brains from patients with AD [29]. Since endocannabi-
noids negatively regulate TNF-α, the downregulation via
CB2 receptors may be a primary mechanism leading to
inhibition of the downstream events including NF-κB
activation, nitric oxide production and leukotriene syn-
thesis [30,31]. Unfortunately, the role of endocannabi-
noids appears to be more complex because these
promiscuous lipids also interact with other targets, such
as peroxisome proliferator-activated receptors and the
vanilloid receptor 1, which mediate the β-amyloid in-
duced neuroinflammation in mice lacking the enzyme
fatty acid amide hydrolase which regulates the metabol-
ism of the endocannabinoid anandamide and other fatty
acid ethanolamides [32]. Thus, agents selectively tar-
geting CB2 receptors could be more advantageous to
treat AD. We speculate that several of the downstream
signaling effects of MH as reported by Lee et al. [1] are
mediated via CB2 receptors. Along this line, the in-
hibition of Iκ-Bα phosphorylation in microglial cells
by anandamide can be reversed by SR144528, a CB2
receptor-selective antagonist [33]. However, the syn-
thetic cannabinoid WIN55212-2, a relatively potent
non-selective CB1/CB2 receptor agonist, has been
shown to inhibit NF-κB in neuronal cells in a receptor-
independent manner, albeit at high concentrations [34].
Thus, MH may well inhibit NF-κB via CB2 receptors
at nM concentrations, or at higher μM concentrations
independently of receptor activation. CB2 receptor ac-
tivation may change the cytokine pattern and shift
the polarization of the microglia towards M2, thus re-
programming macrophages for β-amyloid removal
(Figure 1). An obvious way to assess the involvement
of CB2 receptors in the attenuation of neuroinflamma-
tion by MH would be to use CB2 receptor knockout
mice. Alternatively, the effects of MH may be directly
compared to the effects of honokiol, which is the
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biosynthetic precursor of MH that also targets kinases
and NF-κB, exerting a range of anti-inflammatory effects
in vitro at higher μM concentrations [35,36], but lacks
the potent CB2 receptor affinity [9]. Both strategies
might be used to assess the relative contributions of
each action, namely the CB2 receptor modulation, gen-
eral antioxidative effects or direct inhibition of kinases
and NF-κB.
Discussion
The endocannabinoid system and neuroinflammation
Although AD is currently treated with cholinergic and
glutamatergic therapies, which provide symptomatic
benefit, the pathophysiology of AD is also widely asso-
ciated with inflammation and aberrations of innate im-
munity [37]. Inflammation is not only involved in acute
CNS conditions, such as stroke and traumatic injury,
but it is also a central factor in chronic and neurodegen-
erative conditions such as AD, Parkinson’s disease and
multiple sclerosis [38]. Nevertheless, the inflammation
hypothesis of AD, as attractive as it appears, has not yet
been corroborated in clinical trials. Recent attempts to
treat AD with non-steroidal anti-inflammatory drugs
and the TNF-α blocker entanercept were not successful
[38,39], most probably due to the fundamental bio-
chemical differences between neuroinflammation and
peripheral inflammation [40]. However, novel pleiotropic
anti-inflammatory mechanisms based on modulation of
innate immunity, including the modulation of the endo-
cannabinoid system, may be exploited. Because the CB2
receptor mediates different anti-inflammatory effects via
multiple signaling pathways [22] it was previously sug-
gested to be a drug target to treat neurodegenerative
diseases [17,31]. However, to date only few preclinical
studies have explored the pharmacological effects of
the distinctly different CB2 receptor ligands (full ago-
nists, partial agonists, inverse agonists, silent antagonists
and protean agonists) in models of neuroinflammation
and AD.
CB2 receptor modulation by MH to target AD?
The promising preclinical results obtained with the
novel CB2 receptor ligand MH may spur further re-
search on the role of CB2 receptors in neuroinflamma-
tion in general and AD in particular. The findings




Figure 1 Hypothetical model of how modulation of CB2 receptors may attenuate inflammation in AD. 1. Activated astrocytes, microglia,
and macrophages release proinflammatory cytokines such as IL-1β, IL-6, and TNF-alpha in response to the deposition and accumulation of Aβ
and the release of chemoattractants from damaged neurons. The endocannabinoid system counter regulates such processes and CB2 receptors
seem fundamentally involved in this response. 2. MH modulates CB2 receptors, leading to inhibition of TH1 cytokines and possibly decreased
chemotaxis 3. Decreased inflammation promotes Aβ phagocytosis (clearance) and neuronal viability.
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clearly indicate that MH is orally bioavailable to the
CNS in mice, as well as active at relatively low doses.
This is unexpected given the likely detoxification and
phase II biotransformation of the biphenyl scaffold of
this neolignan [41]. Thus, until the pharmacokinetics
and metabolism of MH are studied it cannot be excluded
that MH may potentially also act as a prodrug. Alterna-
tively, MH crosses the blood–brain barrier and reaches
the nM concentrations necessary to inhibit AChE and to
modulate CB2 receptors, thus exerting a polypharmaco-
logical action on acetylcholine levels and inflammation.
In addition to downregulating cyclooxygenase-2 gene
expression [1], MH also directly inhibits COX1/2 [42],
which may further contribute to its in vivo efficacy.
MH is a relatively rare natural product of plant origin
which is mainly found in the seeds of M. grandiflora, a
tree native to Northern Mexico and the USA [43,44].
Its long use in traditional medicine and its mention in
the United States Pharmacopoia as antimalarial and dia-
phoretic [44,45] suggest a lack of acute toxicity of MH,
a major secondary metabolite in this medicinal plant.
Conclusions
Because of the promising preclinical studies reported in
the past, further studies are indicated to explore the
therapeutic potential of CB2 receptor modulators such
as MH and its CB2 receptor active derivatives [9] for AD
drug discovery.
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